With “hardware guy” John Ternus as frontrunner for the next CEO, can Apple overtake its ex-employees at OpenAI and Meta?

A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...

Adaptive Biotechnologies (ADPT) announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

Genetron Holdings Ltd, a leading precision oncology platform in China also known as Genetron Health, announced on Tuesday ...

The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...

Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...